Litmus email source
Copy source
<!DOCTYPE html><html lang="en" style="background-color:#ffffff;margin:0;padding:0"><head> <title>Scholar Rock</title> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta name="viewport" content="width=device-width"> <!--[if gte mso 9]><xml><o:OfficeDocumentSettings><o:AllowPNG/><o:PixelsPerInch>96</o:PixelsPerInch></o:OfficeDocumentSettings></xml> <![endif]--> <!--[if (gte mso 15)|(IE)]> <style type="text/css"> table{border-collapse:collapse;border-spacing:0;mso-line-height-rule:exactly;mso-margin-bottom-alt:0;mso-margin-top-alt:0;mso-table-lspace:0pt;mso-table-rspace:0pt;} </style> <![endif]--> <!--[if gte mso 9]> <style>li{margin-left:12px !important;mso-special-format:bullet;} </style> <![endif]--> <!--[if gte mso 9]> <style>sup,sub{font-size:100% !important;} </style> <![endif]--> <style>#outlook a{padding:0;}.ReadMsgBody{width:100%;}body,table,td,a{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;}table,td{mso-table-lspace:0pt;mso-table-rspace:0pt;}img{-ms-interpolation-mode:bicubic;}body{margin:0;padding:0;}img{border:0;height:auto;line-height:100%;outline:none;text-decoration:none;}table{border-collapse:collapse!important;border-spacing:0!important;}html,body{margin:0 auto!important;padding:0!important;height:100%!important;width:100%!important;}p{margin:0 !important;padding:0!important;}.img-max{max-width:100%;height:auto;}u+.body .listGmail{margin-left:20px!important;} @media (max-width:640px){u+.body .listGmail{margin-left:14px!important;}u+.body .listGmail li{padding-left:6px!important;} }.nolink a{color:inherit!important;text-decoration:none!important;font-size:inherit!important;font-family:inherit!important;font-weight:inherit!important;line-height:inherit!important;} </style> </head> <body width="100%" style="margin:0;color:#000000;font-family:Arial,Helvetica,Verdana,sans-serif;font-size:16px;line-height:22px;mso-line-height-rule:exactly;-webkit-font-smoothing:antialiased;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;background-color:#ffffff;padding:0;height:100%;width:100%"><center style="width:100%"><div style="display:none;width:0;height:0;max-height:0;line-height:0;mso-hide:all;overflow:hidden;visibility:hidden;padding:0;margin:0;font-size:1px;color:#ffffff; line-height:1px;opacity:0"> Learn more about ISEMBYLD with these helpful resources ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ </div> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#12A166;padding-left:20px;padding-right:20px;padding-top:6px;padding-bottom:6px"><div style="box-sizing:border-box;text-align:center;display:block;margin:0;margin-bottom:0;mso-line-height-rule:exactly;font-family:Arial,Helvetica, sans-serif;font-size:14px;line-height:18px;font-weight:700;color:#ffffff"> <a href="https://www.isembyld.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isi_0350#isi" target="_blank" style="color:#00205B;text-decoration:underline">Important Safety Information</a> | <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_header_0350" target="_blank" style="color:#00205B;text-decoration:underline">Prescribing Information</a></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-bottom:8px;padding-top:8px"><div style="box-sizing:border-box;text-align:center;display:block;margin:0 auto;margin-bottom:12px;"> <a href="https://www.isembyldhcp.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isembyld_hcp_logo_header" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-resources-email/logo-isembyld.png" width="200" height="68" border="0" alt="ISEMBYLD brand logo" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic" class="img-max"></a></div><div style="box-sizing:border-box;display:block;margin:0; margin-bottom:28px;mso-line-height-rule:exactly;text-align:center;font-family:'Arial Black',Arial,Helvetica,sans-serif;font-size:22px;line-height:24px;font-weight:900;color:#00205B">The First and Only <span style="white-space:nowrap;">Muscle-Targeted</span> Treatment Designed to Improve Motor Function in SMA Is Here.<sup style="font-size:70%;line-height:1">1</sup></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica, sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Dear/Hello/Hi/Good morning/Good afternoon/Good evening/Greetings] [Dr/Doctor/Miss/Mr/Mrs/Ms] [Type in recipient’s name]<span style="color:#000000">,</span></p></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom: 16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [It’s a pleasure to meet you over email. In your ongoing efforts to provide the best care for people with SMA, I thought the ISEMBYLD information linked below would be of interest to you. <br><br> I‘m looking forward to meeting you soon. In the interim, I wanted to share some ISEMBYLD information with you. <br><br> It was great to connect with you recently. Based on our conversation, I wanted to share the discussed ISEMBYLD information with you. <br><br> In your ongoing efforts to provide the best care for people with SMA, I thought the ISEMBYLD information linked below would be of interest to you.] </p></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#12A166;padding:20px;padding-left:24px;padding-right:24px"><div style="font-family:Arial,Helvetica,sans-serif;box-sizing:border-box;display:block;margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-size:14px; line-height:18px;font-weight:700;color:#00205B"> ISEMBYLD is the first and only FDA-approved muscle-targeted treatment for adults and pediatric patients aged 2 years and older living with SMA who are currently receiving an SMN2-targeted treatment.<sup style="font-size:70%;line-height:1">1</sup> Below, please find some resources that could be helpful to you and your practice as you get started with ISEMBYLD.<sup style="font-size:70%;line-height:1">1</sup></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-bottom:8px;padding-top:20px"><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif; font-size:16px;line-height:20px;color:#000000">Please see the <b>ISEMBYLD Magnum PI</b> <a href="https://www.isembyldhcp.com/magnum-pi.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=magnum_pi_0350" style="color:#00205B;text-decoration:underline;font-weight:bold;" target="_blank"><u style="color:#00205B">here</u></a></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size: 16px;line-height:20px;color:#000000">Please see the <b>HCP Infusion Guide</b> <a href="https://isembyldhcp.com/hcp-infusion-guide.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=hcp_infusion_guide_0350" style="color:#00205B;text-decoration:underline;font-weight:bold;" target="_blank"><u style="color:#00205B">here</u></a></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif; font-size:16px;line-height:20px;color:#000000">Please see the <b>Patient Infusion Day Brochure</b> <a href="https://isembyldhcp.com/patient-infusion-day-guide.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=patient_infusion_day_guide_0350" style="color:#00205B;text-decoration:underline;font-weight:bold;" target="_blank"><u style="color:#00205B">here</u></a></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left; font-family:Arial,Helvetica,sans-serif;font-size:16px;line-height:20px;color:#000000">Please see the <b>Scholar Rock Supports™ Program Brochure</b> <a href="https://www.scholarrocksupports.com/scholar-rock-supports-brochure.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=srs_program_brochure_0350" style="color:#00205B;text-decoration:underline;font-weight:bold;" target="_blank"><u style="color:#00205B">here</u></a></div><div style="box-sizing:border-box; display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:16px;line-height:20px;color:#000000">Please see the <b>ISEMBYLD Ordering & Distribution Overview</b> <a href="https://www.isembyldhcp.com/ordering-distribution-overview.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=isembyld_ordering_distribution_overview_0350" style="color:#00205B;text-decoration:underline;font-weight:bold;" target="_blank"><u style="color:#00205B">here</u></a></div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0" align="center" style="margin:0 auto;"><tr><td width="600"> <![endif]--> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="max-width:600px;box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;vertical-align:top;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-bottom:8px;padding-top:8px" valign="top"><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family: Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> INDICATION </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:20px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> ISEMBYLD (apitegromab-mstn) is indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 <span style="white-space:nowrap;">(SMN2)‑targeted</span> treatment. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> IMPORTANT SAFETY INFORMATION </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold; font-size:14px;line-height:16px;color:#00205B"> WARNINGS AND PRECAUTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Fractures </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color: #00205B"> ISEMBYLD may increase the risk of fractures, including serious fractures. Use with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> ADVERSE REACTIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> The most common adverse reactions (incidence ≥20% of patients treated with ISEMBYLD and more frequent than placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity. </div><div style="box-sizing: border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> USE IN SPECIFIC POPULATIONS </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Pregnancy and Lactation </div><div style="box-sizing:border-box;text-align:left; display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may cause fetal harm. There are no adequate data on the developmental risk associated with the use of ISEMBYLD in pregnant women. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px; line-height:16px;color:#00205B"> There are no data on the presence of ISEMBYLD in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ISEMBYLD, and any potential adverse effects on the breastfed infant. </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:8px;font-family:Arial,Helvetica, Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Females and Males of Reproductive Potential </div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:normal;font-size:14px;line-height:16px;color:#00205B"> Based on animal data, ISEMBYLD may affect male and/or female reproductive function. </div><div style="box-sizing:border-box;text-align:left;display:block; margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;font-weight:bold;font-size:14px;line-height:16px;color:#00205B"> Please see full <a href="https://scholarrock.com/documents/label/us/ISEMBYLD_PI.pdf?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=prescribing_information_body_0350" target="_blank" style="text-decoration:underline;color:#00205B">Prescribing Information</a>. </div> </td></tr></tbody></table> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" bgcolor="#ffffff" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;background-color:#ffffff;padding:20px;padding-left:24px;padding-right:24px;padding-top:4px"><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height: 18px;font-weight:400;color:#000000"><p style="margin:0;margin-bottom:0;mso-line-height-rule:exactly;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [I’d love to discuss the above and more about ISEMBYLD with you. Please let me know a day, time, and location that works best for you and I will follow up with a meeting invitation. <br><br> I look forward to meeting with you soon. Please reach out with any questions in the meantime. <br><br> After reviewing the material, if you have any questions that you still need addressed, please reach out to me at any time. <br><br> I’d love the opportunity to share more about ISEMBYLD with you. Please let me know a day, time, and location that works best for you and I will follow up with a meeting invitation.] </p></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px; line-height:18px;font-weight:400;color:#FF00FB"> [Sincerely] [Best] [Regards]<span style="color:#000000">,</span></div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock Field Team Member first name and last name] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica, sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock Field Team Member title] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:2px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock Field Team Member phone number] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:20px;text-align:left;font-family:Arial,Helvetica,sans-serif; font-size:14px;line-height:18px;font-weight:400;color:#FF00FB"> [Scholar Rock Field Team Member email address] </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica,sans-serif;font-size:10px;line-height:12px;font-weight:400;color:#000000"> SMA=spinal muscular atrophy; SMN2=survival motor neuron 2. </div><div style="box-sizing:border-box;display:block;margin:0;margin-bottom:16px;text-align:left;font-family:Arial,Helvetica, sans-serif;font-size:10px;line-height:12px;font-weight:400;color:#000000"> <b>Reference:</b><br> <b>1.</b> ISEMBYLD. Prescribing Information. Scholar Rock, Inc; 2026. </div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table> <table border="0" cellpadding="0" cellspacing="0" width="100%" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;width:100%" role="none"><tbody><tr><td align="center" style="box-sizing:border-box;font-family:Arial,Helvetica,Verdana,sans-serif;vertical-align:top;background-color:#ffffff" valign="top"> <!--[if mso]> <table border="0" cellpadding="0" cellspacing="0"><tr><td width="600"> <![endif]--><div style="max-width:600px;margin:0 auto;"> <table align="center" width="100%" border="0" cellpadding="0" cellspacing="0" style="box-sizing:border-box;border-collapse:separate!important;mso-table-lspace:0pt;mso-table-rspace:0pt;" role="none"><tbody><tr><td align="left" style="box-sizing:border-box;background-color:#00205B;padding-bottom:24px;padding-left:20px;padding-right:20px;padding-top:24px"><div style="box-sizing:border-box;text-align:left;display:block;margin:0 auto;margin-bottom:12px;"> <a href="https://scholarrock.com/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=scholar_rock_logo_0350" target="_blank"><img src="https://cdn.scholarrockcommunications.com/campaigns/branded/hcp/2026/outlook-resources-email/footer-logo-scholar-rock.png" width="194" height="48" border="0" alt="" style="max-width:100%;vertical-align:middle;-ms-interpolation-mode:bicubic;display:inline-block"></a></div><div style="box-sizing:border-box;text-align:left;display:block; margin:0;margin-bottom:20px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <a href="https://scholarrock.com/contact-us/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=contact_us_footer_0350" target="_blank" style="color:#ffffff;text-decoration:none;">Contact Us</a> <a href="https://scholarrock.com/privacy-policy/?utm_source=hcp_outlook&utm_medium=email&utm_campaign=hcp_branded&utm_content=privacy_policy_footer_0350" target="_blank" style="color:#ffffff;text-decoration:none;">Privacy Policy</a></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">301 Binney Street, 3rd Floor<br> Cambridge, MA 02142</span></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:12px;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> <span class="nolink">ISEMBYLD and Scholar Rock Supports are trademarks of Scholar Rock.<br> Scholar Rock © 2026. All rights reserved.<br> US-APIT-0350 09/26</span></div><div style="box-sizing:border-box;text-align:left;display:block;margin:0;margin-bottom:0;font-family:Arial,Helvetica,Verdana,sans-serif;color:#ffffff;font-size:10px;line-height:12px;mso-line-height-rule:exactly;font-weight:normal;"> This advertisement is intended only for healthcare professionals in the United States.<br> Reply with “unsubscribe” to be removed from future ISEMBYLD Marketing communications. </div> </td></tr></tbody></table></div> <!--[if mso]> </td></tr></table> <![endif]--> </td></tr></tbody></table></center> </body></html>